Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
JNGHFDrugs in Pipeline
134
Phase 3 Programs
63
Upcoming Catalysts
17
Next Catalyst
This month
Market Overview
Stock performance and key metrics
17 upcoming, 0 past
HR17031 injection
Adult Patients With Type 2 Diabetes
HRS-8427
Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP)
SHR0410 Injection
Pain
SHR3680
Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
SHR8554 Injection
Pain
Hetrombopag Olamine
Idiopathic Thrombocytopenic Purpura
pyrotinib
Non Small Cell Lung
SHR4640 dose1
Gout
Hetrombopag Olamine+Standard Therapy
Severe Aplastic Anemia
SHR0302
Rheumatoid Arthritis
Herombopag tablets
Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Non-Small Cell Lung Cancer With HER2- Mutations
Paclitaxel Injection
Ovarian Cancer
SHR8058 eye drops
Treatment of Dry Eye Disease With Meibomian Gland Dysfunction
SHR4640
Gout
Drug: Pegylated rhG-CSF: 100µg/kg
Breast Cancer
Hetrombopag
Chemotherapy-Induced Thrombocytopenia
Almonertinib
Non-small Cell Lung Cancer
Apatinib
Carcinoma, Hepatocellular
Remimazolam Tosilate
Sedation
Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel
Breast Cancer
SHR8028 eye drops
Dry Eye Disease
Capecitabine tablets
Breast Cancer
KN046
Advanced Pancreatic Ductal Adenocarcinoma
FRSW117
Severe Hemophilia A
SHR-A1811 for Injection
Early-stage or Locally Advanced HER2-positive Breast Cancer
SHR-A1811
Advanced Non-small Cell Lung Cancer
SHR-1210
Gastric Cancer
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin
Non-Small-Cell Lung Cancer
X0002 Spray
KNEE OSTEOARTHRITIS
SHR-1209
Primary Hypercholesterolemia
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Rivoceranib (Apatinib)
Hepatocellular Carcinoma (HCC)
INS068 injection
Type 2 Diabetes
Camrelizumab
Solid Tumor
BP102, paclitaxel, carboplatin
Non-small Cell Lung Cancer(NSCLC)
Paracetamol injection
Post-operative Analgesia
Camrelizumab Plus Chemotherapy
Triple Negative Breast Cancer
SHR-A1811 Injection
Advanced Gastric Cancer
SHR7280 tablets
Female Subjects Undergoing COH in ART to Prevent Early Ovulation
Remimazolam Tosilate for injection
Operative Sedation of Pediatric
camrelizumab； famitinib malate
Cervical Cancer
JSKN003
Advanced Solid Tumor
Noiiglutide Injection
Type 2 Diabetes
SHR-A1811 Injection ； Pertuzumab Injection
HER2-PositiveRecurrent or Metastatic Breast Cancer
SHR7280；Ganirelix Acetate Injection simulant
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
TACE+Camrelizumab+Apatinib mesylate
Hepatocellular Carcinoma
SHR2554; Chidamide analog tablets
Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
68Ga-DOTATOC
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Propofol
Sedation
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate
First-line Treatment of Metastatic Pancreatic Cancer
Apatinib Mesylate
Gastric Cancer
Irinotecan liposome、5-Fluorouracil、Leucovorin
Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy
Rezvilutamide Tablets
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
SHR6390
Advanced Breast Cancer
Famitinib
Colorectal Cancer Metastatic
Propofol Medium and Long Chain Fat Emulsion Injection
Sedation in the ICU
Camrelizumab plus TP
Oral Squamous Cell Carcinoma
Pyrotinib in combination with Capecitabine.
HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate
First-line Treatment of Advanced Pancreatic Cancer
Fluzoparib capsules
Ovarian Cancer
HRS-4357 injection
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
HRS-4642+AG +Adebrelimab
Pancreatic Cancer
COPOX
Gastric Cancer (GC)
Rezvilutamide
Salivary Gland Neoplasm Duct
Mecapegfilgrastim, day 2
Multiple Myeloma
• Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy
Esophageal Squamous Cell Carcinoma (ESCC)
SHR-A1811 Injection + Adebrelimab Injection
HR Positive/HER2 Low Breast Cancer
mFOLFOX7 combined with Camrelizumab and apatinib
Hepatocellular Carcinoma Non-resectable
Paclitaxel for injection (albumin-bound)
Esophageal Squamous Cell Carcinoma
FH-006 for Injection
Malignant Solid Tumor
Propofol Injection.
Local Anesthesia Assisted Sedation
SHR0302 Tablets
Non-segmental Vitiligo
APL-1202 treatment
Non-muscle Invasive Bladder Cancer
RSS0343 Tabella
Adolescent Asthma
SHR-1020
Recurrent or Metastatic Cervical Cancer
KN026 combination
HER2-positive Solid Tumors
mFOLFIRINOX
Advanced Pancreatic Cancer
benzbromarone
Hyperuricemia
JSKN016
Inoperable Locally Advanced HER2-Negative Breast Cancer
SHR2554/CHOP
Peripheral T-cell Lymphoma
SP2086(50 mg q.d.)/Metformin
Type 2 Diabetes
KN019, 5mg/kg
Rheumatoid Arthritis
HR18042
Moderate to Severe Acute Pain
KN026 10 mg/kg QW
Gastric/Gastroesophageal Junction Cancer
SHR-1701
Pancreatic Cancer
SHR117887
Type 2 Diabetes
Adebrelimab
Advanced KRAS G12D Mutant Solid Tumors
FOLFOX4
Advanced Primary Liver Cancer
HS-20004
Diabetes Mellitus, Type 2
SS109
Male
Pegylated rhG-CSF 100μg/kg
Breast Cancer
HRS-9190
Neuromuscular Blockade
HRS-1167 tablets
Prostate Cancer
HRS-4642
Advanced Solid Tumors
HRS4800 tablets
Pain
HRS-6209 Capsules
Breast Cancer
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin
Lung Cancer
HRS-5041 tablets
Prostate Cancer
Fluzoparib+Apatinib
Relapsed Ovarian Cancer
SHR-A1811 combined with Pyrotinib.
HER2-expressing Advanced Solid Tumors
Fluzoparib
Small Cell Lung Cancer
HRG2010(I)
Parkinson's Disease
HR021618
Pain After Abdominal Surgery
HS-10375
Advanced or Metastatic NSCLC
HS-10365 capsules
Nonsmall Cell Lung Cancer
HS-20094
Type 2 Diabetes
SHR7280
Endometriosis
50 mg SP2086
Type 2 Diabetes
SHR 1210+apatinib
Hepatocellular Carcinoma
SHR-3167
Type 2 Diabetes
HRS-4508 tablet
Solid Tumor
SHR0302Base gel
Vitiligo
HRS-6209 in Combination with Fulvestrant
Advanced Unresectable or Metastatic Breast Cancer
SHR-A1904
Advanced Solid Tumors
HRS-6768
Advanced Solid Tumors
SHR- A1811
Gynaecological Malignancies
Meropenem
Hospital-acquired Bacterial Pneumonia (HABP)
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)
Advanced Non-small Cell Lung Cancer
SHR-1314
Moderate-to-severe Chronic Plaque Psoriasis
HR020602 injection
Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol)
HRS-6213
Patients With Solid Tumors
Camrelizumab、Rivoceranib
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
HRS-8364 Tablet
Solid Tumor
SHR2554; SHR-A2102
Locally Advanced or Metastatic Non-small Cell Lung Cancer
FH-006
Malignant Solid Tumor
Insulin Degludec
Type 2 Diabetes
HR19042 Capsules
Autoimmune Hepatitis
SHR-1703
Asthma With Eosinophilic Phenotype
SHR6390+anatrozole
Breast Cancer
Abiraterone Acetate Tablets (I)
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Mecapegfilgrastim
Metastatic Breast Cancer
Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
HR17031 injection | Phase 3 | Adult Patients With Type 2 Diabetes | - | - |
HRS-8427 | Phase 3 | Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP) | - | - |
SHR0410 Injection | Phase 3 | Pain | - | - |
SHR3680 | Phase 3 | Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | - | - |
SHR8554 Injection | Phase 3 | Pain | - | - |
Hetrombopag Olamine | Phase 3 | Idiopathic Thrombocytopenic Purpura | - | - |
pyrotinib | Phase 3 | Non Small Cell Lung | - | - |
SHR4640 dose1 | Phase 3 | Gout | - | - |
Hetrombopag Olamine+Standard Therapy | Phase 3 | Severe Aplastic Anemia | - | - |
SHR0302 | Phase 3 | Rheumatoid Arthritis | - | - |
Herombopag tablets | Phase 3 | Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery | - | - |
Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin | Phase 3 | Non-Small Cell Lung Cancer With HER2- Mutations | - | - |
Paclitaxel Injection | Phase 3 | Ovarian Cancer | - | - |
SHR8058 eye drops | Phase 3 | Treatment of Dry Eye Disease With Meibomian Gland Dysfunction | - | - |
SHR4640 | Phase 3 | Gout | - | - |
Drug: Pegylated rhG-CSF: 100µg/kg | Phase 3 | Breast Cancer | - | - |
Hetrombopag | Phase 3 | Chemotherapy-Induced Thrombocytopenia | - | - |
Almonertinib | Phase 3 | Non-small Cell Lung Cancer | - | - |
Apatinib | Phase 3 | Carcinoma, Hepatocellular | - | - |
Remimazolam Tosilate | Phase 3 | Sedation | - | - |
Capecitabine/Eribulin/Gemcitabine/Paclitaxel/Nab-paclitaxel | Phase 3 | Breast Cancer | - | - |
SHR8028 eye drops | Phase 3 | Dry Eye Disease | - | - |
Capecitabine tablets | Phase 3 | Breast Cancer | - | - |
KN046 | Phase 3 | Advanced Pancreatic Ductal Adenocarcinoma | - | - |
FRSW117 | Phase 3 | Severe Hemophilia A | - | - |
SHR-A1811 for Injection | Phase 3 | Early-stage or Locally Advanced HER2-positive Breast Cancer | - | - |
SHR-A1811 | Phase 3 | Advanced Non-small Cell Lung Cancer | - | - |
SHR-1210 | Phase 3 | Gastric Cancer | - | - |
SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
X0002 Spray | Phase 3 | KNEE OSTEOARTHRITIS | - | - |
SHR-1209 | Phase 3 | Primary Hypercholesterolemia | - | - |
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | - | - |
Rivoceranib (Apatinib) | Phase 3 | Hepatocellular Carcinoma (HCC) | - | - |
INS068 injection | Phase 3 | Type 2 Diabetes | - | - |
Camrelizumab | Phase 3 | Solid Tumor | - | - |
BP102, paclitaxel, carboplatin | Phase 3 | Non-small Cell Lung Cancer(NSCLC) | - | - |
Paracetamol injection | Phase 3 | Post-operative Analgesia | - | - |
Camrelizumab Plus Chemotherapy | Phase 3 | Triple Negative Breast Cancer | - | - |
SHR-A1811 Injection | Phase 3 | Advanced Gastric Cancer | - | - |
SHR7280 tablets | Phase 3 | Female Subjects Undergoing COH in ART to Prevent Early Ovulation | - | - |
Remimazolam Tosilate for injection | Phase 3 | Operative Sedation of Pediatric | - | - |
camrelizumab； famitinib malate | Phase 3 | Cervical Cancer | - | - |
JSKN003 | Phase 3 | Advanced Solid Tumor | - | - |
Noiiglutide Injection | Phase 3 | Type 2 Diabetes | - | - |
SHR-A1811 Injection ； Pertuzumab Injection | Phase 3 | HER2-PositiveRecurrent or Metastatic Breast Cancer | - | - |
SHR7280；Ganirelix Acetate Injection simulant | Phase 3 | Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation | - | - |
TACE+Camrelizumab+Apatinib mesylate | Phase 3 | Hepatocellular Carcinoma | - | - |
SHR2554; Chidamide analog tablets | Phase 3 | Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy | - | - |
68Ga-DOTATOC | Phase 3 | Advanced Gastroenteropancreatic Neuroendocrine Tumor | - | - |
Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan | Phase 3 | HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | - | - |
Propofol | Phase 3 | Sedation | - | - |
Irinotecan Hydrochloride Liposome Injection (II); Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Metastatic Pancreatic Cancer | - | - |
Apatinib Mesylate | Phase 3 | Gastric Cancer | - | - |
Irinotecan liposome、5-Fluorouracil、Leucovorin | Phase 3 | Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy | - | - |
Rezvilutamide Tablets | Phase 3 | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | - | - |
SHR6390 | Phase 3 | Advanced Breast Cancer | - | - |
Famitinib | Phase 3 | Colorectal Cancer Metastatic | - | - |
Propofol Medium and Long Chain Fat Emulsion Injection | Phase 3 | Sedation in the ICU | - | - |
Camrelizumab plus TP | Phase 3 | Oral Squamous Cell Carcinoma | - | - |
Pyrotinib in combination with Capecitabine. | Phase 3 | HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane | - | - |
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate | Phase 3 | First-line Treatment of Advanced Pancreatic Cancer | - | - |
Fluzoparib capsules | Phase 3 | Ovarian Cancer | - | - |
HRS-4357 injection | Phase 3 | PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer | - | - |
HRS-4642+AG +Adebrelimab | Phase 2 | Pancreatic Cancer | - | - |
COPOX | Phase 2 | Gastric Cancer (GC) | - | - |
Rezvilutamide | Phase 2 | Salivary Gland Neoplasm Duct | - | - |
Mecapegfilgrastim, day 2 | Phase 2 | Multiple Myeloma | - | - |
• Adebrelimab and nab-paclitaxel, carboplatin in Combination With radiotherapy | Phase 2 | Esophageal Squamous Cell Carcinoma (ESCC) | - | - |
SHR-A1811 Injection + Adebrelimab Injection | Phase 2 | HR Positive/HER2 Low Breast Cancer | - | - |
mFOLFOX7 combined with Camrelizumab and apatinib | Phase 2 | Hepatocellular Carcinoma Non-resectable | - | - |
Paclitaxel for injection (albumin-bound) | Phase 2 | Esophageal Squamous Cell Carcinoma | - | - |
FH-006 for Injection | Phase 2 | Malignant Solid Tumor | - | - |
Propofol Injection. | Phase 2 | Local Anesthesia Assisted Sedation | - | - |
SHR0302 Tablets | Phase 2 | Non-segmental Vitiligo | - | - |
APL-1202 treatment | Phase 2 | Non-muscle Invasive Bladder Cancer | - | - |
RSS0343 Tabella | Phase 2 | Adolescent Asthma | - | - |
SHR-1020 | Phase 2 | Recurrent or Metastatic Cervical Cancer | - | - |
KN026 combination | Phase 2 | HER2-positive Solid Tumors | - | - |
mFOLFIRINOX | Phase 2 | Advanced Pancreatic Cancer | - | - |
benzbromarone | Phase 2 | Hyperuricemia | - | - |
JSKN016 | Phase 2 | Inoperable Locally Advanced HER2-Negative Breast Cancer | - | - |
SHR2554/CHOP | Phase 2 | Peripheral T-cell Lymphoma | - | - |
SP2086(50 mg q.d.)/Metformin | Phase 2 | Type 2 Diabetes | - | - |
KN019, 5mg/kg | Phase 2 | Rheumatoid Arthritis | - | - |
HR18042 | Phase 2 | Moderate to Severe Acute Pain | - | - |
KN026 10 mg/kg QW | Phase 2 | Gastric/Gastroesophageal Junction Cancer | - | - |
SHR-1701 | Phase 2 | Pancreatic Cancer | - | - |
SHR117887 | Phase 2 | Type 2 Diabetes | - | - |
Adebrelimab | Phase 2 | Advanced KRAS G12D Mutant Solid Tumors | - | - |
FOLFOX4 | Phase 2 | Advanced Primary Liver Cancer | - | - |
HS-20004 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
SS109 | Phase 2 | Male | - | - |
Pegylated rhG-CSF 100μg/kg | Phase 2 | Breast Cancer | - | - |
HRS-9190 | Phase 2 | Neuromuscular Blockade | - | - |
HRS-1167 tablets | Phase 2 | Prostate Cancer | - | - |
HRS-4642 | Phase 2 | Advanced Solid Tumors | - | - |
HRS4800 tablets | Phase 2 | Pain | - | - |
HRS-6209 Capsules | Phase 2 | Breast Cancer | - | - |
FH-006 ; SHR-1316 ; BP102 ; Cisplatin ; Carboplatin | Phase 2 | Lung Cancer | - | - |
HRS-5041 tablets | Phase 2 | Prostate Cancer | - | - |
Fluzoparib+Apatinib | Phase 2 | Relapsed Ovarian Cancer | - | - |
SHR-A1811 combined with Pyrotinib. | Phase 2 | HER2-expressing Advanced Solid Tumors | - | - |
Fluzoparib | Phase 2 | Small Cell Lung Cancer | - | - |
HRG2010(I) | Phase 2 | Parkinson's Disease | - | - |
HR021618 | Phase 2 | Pain After Abdominal Surgery | - | - |
HS-10375 | Phase 2 | Advanced or Metastatic NSCLC | - | - |
HS-10365 capsules | Phase 2 | Nonsmall Cell Lung Cancer | - | - |
HS-20094 | Phase 2 | Type 2 Diabetes | - | - |
SHR7280 | Phase 2 | Endometriosis | - | - |
50 mg SP2086 | Phase 2 | Type 2 Diabetes | - | - |
SHR 1210+apatinib | Phase 2 | Hepatocellular Carcinoma | - | - |
SHR-3167 | Phase 2 | Type 2 Diabetes | - | - |
HRS-4508 tablet | Phase 2 | Solid Tumor | - | - |
SHR0302Base gel | Phase 2 | Vitiligo | - | - |
HRS-6209 in Combination with Fulvestrant | Phase 2 | Advanced Unresectable or Metastatic Breast Cancer | - | - |
SHR-A1904 | Phase 2 | Advanced Solid Tumors | - | - |
HRS-6768 | Phase 2 | Advanced Solid Tumors | - | - |
SHR- A1811 | Phase 2 | Gynaecological Malignancies | - | - |
Meropenem | Phase 2 | Hospital-acquired Bacterial Pneumonia (HABP) | - | - |
KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection) | Phase 2 | Advanced Non-small Cell Lung Cancer | - | - |
SHR-1314 | Phase 2 | Moderate-to-severe Chronic Plaque Psoriasis | - | - |
HR020602 injection | Phase 2 | Used to Induce and Implement General Anesthesia in Combination With Sedative Anesthetics (Such as Propofol) | - | - |
HRS-6213 | Phase 2 | Patients With Solid Tumors | - | - |
Camrelizumab、Rivoceranib | Phase 2 | Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | - | - |
HRS-8364 Tablet | Phase 2 | Solid Tumor | - | - |
SHR2554; SHR-A2102 | Phase 2 | Locally Advanced or Metastatic Non-small Cell Lung Cancer | - | - |
FH-006 | Phase 2 | Malignant Solid Tumor | - | - |
Insulin Degludec | Phase 2 | Type 2 Diabetes | - | - |
HR19042 Capsules | Phase 2 | Autoimmune Hepatitis | - | - |
SHR-1703 | Phase 2 | Asthma With Eosinophilic Phenotype | - | - |
SHR6390+anatrozole | Phase 2 | Breast Cancer | - | - |
Abiraterone Acetate Tablets (I) | Phase 2 | Metastatic Castration-resistant Prostate Cancer (mCRPC) | - | - |
Mecapegfilgrastim | Phase 2 | Metastatic Breast Cancer | - | - |
Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment | Phase 2 | Breast Cancer | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's drug pipeline?→
CatalystAlert tracks 134 drug candidates in Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JNGHF) pipeline across Phase 3, Phase 2. Its lead program is HR17031 injection (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's next FDA catalyst?→
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's (JNGHF) next tracked catalyst is a Phase 3 expected October 31, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track JNGHF biotech catalysts?→
Add JNGHF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.